Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of rIX-FP in Hemophilia B
NCT01496274Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Feb 2012
- Primary completion
- Jul 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 10
01
Overview
A Phase 3 trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by CSL Limited. Started Feb 2012; status: completed.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01496274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496274.